Rein Therapeutics (NASDAQ:RNTX) Given “Hold” Rating at Brookline Capital Management

Brookline Capital Management reaffirmed their hold rating on shares of Rein Therapeutics (NASDAQ:RNTX) in a research note issued to investors on Tuesday morning,Benzinga reports.

Rein Therapeutics Stock Performance

Shares of RNTX stock opened at $1.10 on Tuesday. Rein Therapeutics has a 1 year low of $1.04 and a 1 year high of $4.40. The company’s 50 day moving average is $1.42. The stock has a market capitalization of $25.36 million, a P/E ratio of -0.41 and a beta of 1.31.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Equities research analysts expect that Rein Therapeutics will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rein Therapeutics

Institutional investors have recently modified their holdings of the stock. BIOS Capital Management LP acquired a new stake in shares of Rein Therapeutics during the 2nd quarter valued at about $2,367,000. Voss Capital LP acquired a new position in shares of Rein Therapeutics in the second quarter worth $2,007,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Rein Therapeutics during the second quarter worth $716,000. Cable Car Capital LP acquired a new position in Rein Therapeutics in the second quarter valued at $588,000. Finally, Sigma Planning Corp purchased a new stake in shares of Rein Therapeutics in the second quarter valued at about $387,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.